Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Dermatology · Lupus Erythematosus Tumidus

Lupus Tumidus vs Jessner's: What is the Difference?

At a Glance

Lupus Erythematosus Tumidus (LET) and Jessner's Lymphocytic Infiltration are nearly identical skin conditions that cause red, swollen patches in response to sun exposure. They do not cause scarring, rarely affect internal organs, and are treated identically with sun protection, topical creams, and antimalarial medications.

If your doctor mentioned Jessner’s lymphocytic infiltration (often just called “Jessner’s”) while discussing your skin, it is completely normal to be confused about how this relates to Lupus Erythematosus Tumidus (LET). The short answer is that these two conditions are so remarkably similar that many medical experts consider them to be part of the exact same disease spectrum [1][2]. Whether they are identical twins or just very close cousins is a matter of ongoing debate in dermatology [1][3]. However, for you as a patient, the most important thing to know is that they look the same, behave the same, and are treated the exact same way.

Why They Are Easily Confused

To the naked eye—and often even to an expert dermatologist—LET and Jessner’s look identical. Both conditions typically present with:

  • Red, swollen patches: They form raised, hive-like plaques or nodules that feel firm and indurated to the touch [1][4].
  • Sun triggers (Photosensitivity): Both conditions are heavily triggered or worsened by exposure to ultraviolet (UV) light [4][5]. You might notice new spots appearing hours or days after spending time outdoors or even sitting near a sunny window.
  • No permanent scarring: Unlike some other forms of cutaneous lupus (like discoid lupus), both LET and Jessner’s are intermittent and benign. When the spots heal, they fade away entirely without leaving behind scars, skin thinning (atrophy), or permanent color changes [4][6].
  • Low systemic risk: When patients hear the word “lupus,” they often worry about systemic lupus erythematosus (SLE) and internal organ damage. Fortunately, LET is rarely associated with the development of SLE, and Jessner’s is strictly a skin condition [7][8].

The Ongoing Medical Debate

Because the two conditions behave so similarly on the outside, dermatologists rely on skin biopsies to look at the cells under a microscope. However, even under a microscope, they share a core feature: a dense gathering of immune cells (lymphocytes) around the blood vessels and hair follicles in the skin [9][7].

The debate arises because some researchers believe they can spot subtle microscopic clues to tell them apart. To complicate matters further, a test called Direct Immunofluorescence (DIF)—which looks for glowing immune proteins in the skin and is often positive in other forms of lupus—is typically negative in both LET and Jessner’s, making them even harder to distinguish [4].

When looking closely under the microscope, pathologists sometimes check for:

  • Dermal mucin: This is a jelly-like substance in the skin. While it is considered a classic sign of lupus (LET), some studies show it is actually present in both conditions [7][10].
  • Specific immune cells: Pathologists may look for a specific type of cell called a plasmacytoid dendritic cell. A high number of these cells might point slightly more toward LET [10]. You can ask your doctor if your biopsy report mentioned these cells if you are looking for more clarity.

Because telling them apart is so challenging, researchers are even investigating computer-aided image analysis to help accurately distinguish between chronic cutaneous lupus and Jessner’s [11]. Ultimately, LET is formally classified as a distinct subtype of cutaneous lupus, while Jessner’s has historically been called a “pseudolymphoma” (a harmless gathering of immune cells) [3][10]. In daily clinic life, many doctors use the terms almost interchangeably.

What This Means for Your Treatment

If your diagnosis is hovering between LET and Jessner’s, try not to worry about the exact label. Because the underlying mechanism (immune cells reacting to UV light) is the same, your treatment plan will not change based on which name your doctor uses [1].

The approach for both includes:

  • Strict sun protection: This is the most critical step. Daily use of broad-spectrum sunscreen, UPF-rated clothing, and avoiding peak sun hours are required to prevent flare-ups [4]. Remember that UVA rays can easily penetrate car and office windows.
  • Topical medications: Prescription steroid creams or ointments are often the first step to calm down active red patches [4]. Your doctor may also suggest non-steroidal alternatives, like topical calcineurin inhibitors, for long-term management.
  • Antimalarial pills: If the spots are widespread or stubborn, doctors use oral medications like hydroxychloroquine. These drugs help quiet the skin’s overactive immune response to UV light, and they are the standard of care for both LET and Jessner’s [12][13]. It is important to know that these medications can have a delayed response, and it may take several weeks to months to see their full effect [14].

Whether your chart says Lupus Tumidus or Jessner’s Lymphocytic Infiltration, the focus of your care team will remain exactly the same: protecting your skin from the sun and safely calming the inflammation.

Common questions in this guide

What is the main difference between Lupus Tumidus and Jessner's?
To the naked eye, these two conditions look and behave identically, causing red, sun-triggered patches that do not scar. The only potential differences are subtle microscopic clues seen on a skin biopsy, and many experts actually consider them part of the same disease spectrum.
Will Jessner's or Lupus Tumidus turn into systemic lupus?
The risk of either condition developing into systemic lupus erythematosus (SLE) is very low. Jessner's is strictly a skin condition, and Lupus Erythematosus Tumidus rarely involves internal organs.
How are LET and Jessner's treated?
Both conditions are treated exactly the same way. The primary treatments include strict sun protection, prescription steroid creams to calm active patches, and sometimes oral antimalarial pills like hydroxychloroquine for stubborn spots.
Can sun through windows trigger Lupus Tumidus or Jessner's?
Yes, UVA rays can easily penetrate car and office windows and trigger flare-ups for both conditions. Daily use of broad-spectrum sunscreen and sun-protective clothing is highly recommended even when you are indoors near sunny windows.
Does Lupus Tumidus leave permanent scars?
No, unlike some other forms of cutaneous lupus, Lupus Erythematosus Tumidus and Jessner's are benign and intermittent. When the red spots heal, they fade entirely without leaving scars, color changes, or permanently thinning the skin.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my skin biopsy report specifically mention "dermal mucin" or "plasmacytoid dendritic cells" to help clarify the diagnosis?
  2. 2.Because these conditions are triggered by UV light, should I be concerned about UVA exposure through my car or office windows?
  3. 3.If my spots aren't responding to topical treatments, at what point should we consider starting an oral medication like hydroxychloroquine?
  4. 4.Do I need baseline bloodwork to confirm there is no systemic lupus involvement, even though the risk is very low?
  5. 5.Should I use my prescribed topical treatments every day as a preventative measure, or only when new spots begin to appear?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Lupus Erythematosus Tumidus Misdiagnosed as Erythema Nodosum from Coccidioidomycosis.

    Garcia B, Hasnaoui A, Ramdass PVAK

    Case reports in dermatology 2024; (16(1)):128-132 doi:10.1159/000538737.

    PMID: 39015404
  2. 2

    Uncommon Non-Infectious Annular Dermatoses.

    Maurelli M, Colato C, Gisondi P, Girolomoni G

    Indian journal of dermatology 2022; (67(3)):313 doi:10.4103/ijd.ijd_743_21.

    PMID: 36386081
  3. 3

    Lupus erythematosus tumidus: clinical perspectives.

    Patsinakidis N, Kautz O, Gibbs BF, Raap U

    Clinical, cosmetic and investigational dermatology 2019; (12()):707-719 doi:10.2147/CCID.S166723.

    PMID: 31632119
  4. 4

    Lupus Erythematosus Tumidus as a Distinct Uncommon Subtype of Cutaneous Lupus Erythematosus: A Case Report and Review.

    Camisa C, Papavero V

    Cureus 2024; (16(4)):e59140 doi:10.7759/cureus.59140.

    PMID: 38803774
  5. 5

    Tumid Lupus Erythematosus and Systemic Lupus Erythematosus: A Report on Their Rare Coexistence.

    Jatwani K, Chugh K, Osholowu OS, Jatwani S

    Cureus 2020; (12(4)):e7545 doi:10.7759/cureus.7545.

    PMID: 32377493
  6. 6

    Lupus Erythematosus Tumidus Clinical Characteristics and Treatment: A Retrospective Review of 25 Patients.

    Pona A, Cardenas-de la Garza JA, Broderick A, et al.

    Cutis 2022; (109(6)):330-332 doi:10.12788/cutis.0544.

    PMID: 35960984
  7. 7

    Lupus Erythematosus Tumidus: Clinical and Pathological Features in a Series of 20 Patients.

    Magaña M, Castellanos G, Meurehg CC, Magaña-Mainero MR

    The American Journal of dermatopathology 2022; (44(7)):469-477 doi:10.1097/DAD.0000000000002019.

    PMID: 35704910
  8. 8

    Tumid lupus erythematosus and systemic lupus erythematosus: a rare coexistence.

    Ali A, Woods A, Porter C, Feldman SR

    BMJ case reports 2021; (14(10)) doi:10.1136/bcr-2021-245196.

    PMID: 34706914
  9. 9

    Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder Mimicking Jessner Lymphocytic Infiltrate and Tumid Lupus-A Report of Two Cases.

    Yi LG, Gru AA

    The American Journal of dermatopathology 2021; (43(12)):e293-e297 doi:10.1097/DAD.0000000000001982.

    PMID: 34001748
  10. 10

    Lupus Erythematosus Tumidus with Pseudolymphomatous Infiltrates: A Case Report.

    Umeda Y, Ito K, Ansai S, et al.

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2020; (87(2)):100-103 doi:10.1272/jnms.JNMS.2020_87-208.

    PMID: 32418941
  11. 11

    Differentiation of Jessner's Lymphocytic Infiltration of the Skin from Various Chronic Cutaneous Lupus Erythematosus Subtypes by Quantitative Computer-Aided Image Analysis.

    Kim IS, Kim BR, Youn SW

    Dermatology (Basel, Switzerland) 2016; (232(1)):57-63 doi:10.1159/000440648.

    PMID: 26458204
  12. 12

    Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.

    Chasset F, Bouaziz JD, Costedoat-Chalumeau N, et al.

    The British journal of dermatology 2017; (177(1)):188-196 doi:10.1111/bjd.15312.

    PMID: 28112801
  13. 13

    Hydroxychloroquine-induced generalized myopathy in a patient with lupus tumidus: a case report.

    Verdelli A, Massi D, Maio V, et al.

    Dermatology reports 2024; (16(2)):9771 doi:10.4081/dr.2023.9771.

    PMID: 38979520
  14. 14

    Clinical, Histopathological, and Therapeutic Features in Lupus Erythematosus Tumidus: A Retrospective Study.

    La Rotta-Higuera E, Morgado-Carrasco D, Mansilla-Polo M, et al.

    Actas dermo-sifiliograficas 2025; (116(6)):628-632 doi:10.1016/j.ad.2024.02.038.

    PMID: 39947587

This page compares Lupus Erythematosus Tumidus and Jessner's Lymphocytic Infiltration for educational purposes. Always consult your dermatologist for an accurate diagnosis and personalized treatment plan.

Get notified when new evidence is published on Rare cutaneous lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.